載入中
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
前收盤價
US$1.63
+US$0.06 · +3.82%
盤中時間採用ET。市場資料可能有所延遲。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日內區間
目前US$1.63
52週區間
目前US$1.63
盤中時間採用ET。市場資料可能有所延遲。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日內區間
目前US$1.63
52週區間
目前US$1.63
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1527.82萬 EUR | 1890.5萬 EUR | 651.4萬 EUR | 359.4萬 EUR | 133.5萬 EUR |
| 銷貨成本 | 259.63萬 EUR | — | — | — | — |
| 毛利 | 1268.19萬 EUR | 1890.5萬 EUR | 651.4萬 EUR | 359.4萬 EUR | 133.5萬 EUR |
| 研究與開發 | 4071.79萬 EUR | 3635.6萬 EUR | 2514.8萬 EUR | 5086.7萬 EUR | 4222萬 EUR |
| 銷售、一般及管理費用 | 1506萬 EUR | 1366.1萬 EUR | 1623.6萬 EUR | 1865.1萬 EUR | 1736.8萬 EUR |
| 營業費用 | 5483.68萬 EUR | 4937.7萬 EUR | 3837.3萬 EUR | 6875.3萬 EUR | 5854.5萬 EUR |
| 利息收入 | 224.09萬 EUR | 325.1萬 EUR | 259.3萬 EUR | 10.6萬 EUR | 5000 EUR |
| 利息支出 | 86.64萬 EUR | 107.7萬 EUR | 120.3萬 EUR | 512.7萬 EUR | 340.5萬 EUR |
| 折舊和攤銷 | 270.3萬 EUR | 276.1萬 EUR | 251.3萬 EUR | 252.1萬 EUR | 232.9萬 EUR |
| 營業利益 | −4215.49萬 EUR | −3047.2萬 EUR | −3185.9萬 EUR | −6515.9萬 EUR | −5721萬 EUR |
| 淨利 | −4051.91萬 EUR | −2776.3萬 EUR | −2811.9萬 EUR | −6442.4萬 EUR | −6074萬 EUR |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.00
上漲空間 84.05%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
